Publicações

A Phase Iii Efficacy and Safety Study of the Proposed Rituximab Biosimilar Gp2013 Versus Rituximab in Patients with Previously Untreated Advanced Follicular Lymphoma

AuthID
P-00R-BM2

Author(s)

Jurczak, W

Ilidia, M

Govindbabu, KS

Eduardo, M

Ascuncion, EM

Giri, P

Nelson, C

Juliana, P

Luiza, A

Sergey, A

Dzhelil, O

Pultar, P

Cherfi, A

Zhu, P

Amersdorffer, J

Tipo de Documento

Abstract

Year published

2016

Publicado

in BLOOD, ISSN: 0006-4971

Volume: 128, Número: 22

Conference

58Th Annual Meeting and Exposition of the American-Society-Of-Hematology (Ash), Date: DEC 03-06, 2016, Location: San Diego, CA, Patrocinadores: Amer Soc Hematol

Indexing

Wos^®

Google Scholar^®

Metadata
Fontes

Publication Identifiers

DOI: 10.1182/blood.v128.22.1809.1809

Wos: WOS:000394452307119

Source Identifiers

ISSN: 0006-4971

Export Publication Metadata

Lista Marked

Adicionar à lista Marked

Info

At this moment we don't have any links to full text documens.

A Phase Iii Efficacy and Safety Study of the Proposed Rituximab Biosimilar Gp2013 Versus Rituximab in Patients with Previously Untreated Advanced Follicular Lymphoma

Links Úteis

Ajuda

Autenticação Federada (Clique na imagem)

A Phase Iii Efficacy and Safety Study of the Proposed Rituximab Biosimilar Gp2013 Versus Rituximab in Patients with Previously Untreated Advanced Follicular Lymphoma

Links Úteis

Ajuda